Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics
Source: SeekingAlpha
2026-01-07 17:11:14 ET
Exact Sciences Corporation's ( EXAS ) share price surged in late November 2025, after Abbott Laboratories ( ABT ) made an acquisition offer at a sizeable premium. The acquisition is notable due to both its size, and the fact that it is an all cash offer. It is also interesting because a fairly strong argument can be made that Exact Sciences' competitive positioning has been deteriorating....
Read the full article on Seeking Alpha
For further details see:
Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics
Exact Sciences Corporation
NASDAQ: EXAS
EXAS Trading
-0.04% G/L:
$103.88 Last:
356,452 Volume:
$103.81 Open:
EXAS Latest News
March 17, 2026 04:31:00 pm
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
March 04, 2026 09:00:00 am
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
March 03, 2026 10:00:00 am
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
February 25, 2026 09:40:00 am
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
EXAS Stock Data
$19,584,719,665
187,197,642
0.09%
291
N/A
Medical Diagnostics & Screening
Healthcare
US
Madison
